4D Molecular Therapeutics Inc. Company Profile
NASDAQ: FDMTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
4D Molecular Therapeutics at a glance
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in EmeryVille, CA. 4D Molecular Therapeutics is led by Dr. David H. Kirn M.D. and employs about 196 people. The company's shares have traded publicly since 2020.
At a market capitalization of $576.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001650648, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does 4D Molecular Therapeutics do?
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Business description based on the company's public filings.
Company information
- Legal name
- 4D Molecular Therapeutics Inc.
- Ticker
- NASDAQ: FDMT
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. David H. Kirn M.D.
- Employees
- 196
- Headquarters
- 5858 Horton Street, EmeryVille, CA, United States
- Phone
- 510 505 2680
- Website
- 4dmoleculartherapeutics.com
- IPO year
- 2020
- Market cap
- $576.76M
- SEC CIK
- 0001650648
- Latest annual report
- 10-K · Mar 18, 2026
Companies similar to 4D Molecular Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CGEMCullinan Therapeutics Inc. | 8.89 | -1.98% | $577.15M | vs FDMT |
| ENTXEntera Bio Ltd. | 3.31 | +0.76% | $575.53M | vs FDMT |
| DBVTDBV Technologies S.A. ADR | 9.02 | -4.25% | $566.82M | vs FDMT |
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs FDMT |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs FDMT |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs FDMT |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs FDMT |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs FDMT |